Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative ...

Cybin is currently advancing its CYB003 program into a critical Phase 3 stage, prompting Canaccord to increase its forecast for research ... a Buy rating on the stock. In terms of development ...

meanwhile, raised its target to $25 from $6, reflecting the potential upside based on CYB003’s progress and ongoing Phase 3 trials. Still, Cybin’s stock has seen a 19% decline year-to-date.

In September 2020, the company listed its shares on the Nasdaq stock exchange ... Founded in 2019, Cybin went public in 2020 on Canada's NEO Exchange through a reverse takeover of Clarmin ...